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Background and Purpose—The natural history, causative factors, and outcomes of patients with cerebral venous
thrombosis from Asia and Middle East have not been well described. This descriptive multicenter study describes the
results for cerebral venous thrombosis patients in South Asia and the Middle East.
Methods—The retrospective and prospective data of patients with radiologically confirmed cerebral venous thrombosis
were collected from 4 centers located in Pakistan and United Arab Emirates. The demographic, clinical, radiological,
and outcome data were recorded and analyzed. Primary outcome was death or dependency (modified Rankin score 2)
at the time of hospital discharge.
Results—This study included 109 patients with cerebral venous thrombosis; the presenting features most commonly being
observed were headache (81%), focal motor deficits (45%), seizures (39%), and mental status changes (37%). Important
predisposing factors included systemic and central nervous system infection (18%), postpartum state (17%),
hyperhomocystinemia (9%), genetic thrombophilia (5%), and oral contraceptive pill use (3%). Ninety-six (67%) patients
received therapeutic anticoagulation. Seven patients died and 43 had poor outcome at discharge. Focal motor deficits
(OR, 2.93; 95% CI, 1.2–7.5; P0.018) and hemorrhagic infarctions (OR, 2.81; 95% CI, 1.04–7.85; P0.041) were
independent predictors of unfavorable outcome at discharge. Hemorrhagic infarction was the most significant factor of
long-term unfavorable outcome (OR, 5.87; 95% CI, 1.49–23.02; P0.011).
Conclusions—Infections and postpartum state were the most common predisposing factors for cerebral venous thrombosis
in this cohort. Most patients (67%) were treated with anticoagulation therapy. Almost 50% of patients were dead or
disabled at discharge. (Stroke. 2008;39:2707-2711.)
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Cerebral venous thrombosis (CVT) is an uncommon causeof stroke with extremely diverse clinical features, pre-
disposing factors, brain imaging findings, and outcome.1 Its
prevalence rate is 5 per 1 million and often affects younger
age groups.2 It accounts for 0.5% of all strokes.2 This disease
may be more common in the South Asian region.
Banerjee et al,3 in their autopsy series during late 1980s,
found that CVT accounts for 10% of all strokes. Recently,
Panagariya et al4 reported that CVT accounts for 17%
(64/375) of all strokes. They4 also noted that CVT accounts
for half of all strokes in young people. However, they did not
mention the cut-off age for young stroke. Another interesting
finding they noted was that 38% of all women who
experienced stroke had venous stroke.4 There may be sub-
stantial differences in predisposing factors, presentations,
therapeutic options, and outcome between developed and
developing countries. Though comparison of hospital-based
studies may be difficult, these provide important and essential
information, especially for relatively uncommon diseases.
Despite the fact that community- or population-based studies
provide more accurate data regarding disease burden, risk
factor prevalence, and long-term outcomes, the hospital-
based studies provide useful and reliable information about
characteristics of the disease, because these patients are
well-investigated and more closely followed-up, especially
during acute course of illness.
International Study on Cerebral Vein and Dural Sinus
Thrombosis (ISCVT) reported obstetric CVT in only 20% of
cases as compared to reports from Mexico and India, which
report a much higher frequency.5–7 In addition, there is
variability among different developing countries. Daif et al8
from Saudi Arabia report 25% of the patients in their series as
having Bechet disease and only 1 out of 40 patients being in
postpartum period. The published literature9–13 related to
CVT from Pakistan is limited to only a few case reports or
small case series. Data for this study were collected from 4
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centers, located in 2 different countries of Asia. Our aim was
to characterize clinical presentations, risk factors, clinical
course, and outcome of the disease in 2 countries that, though
geographically separated, share a common feature of having
a predominantly South Asian population.
Materials and Methods
Patients (age 10 years or older) admitted consecutively to 4 tertiary
care centers (The Aga Khan University Hospital and Liaquat
National Hospital, Karachi, Pakistan; Shifa International Hospital,
Islamabad, Pakistan; and Rashid Hospital, Dubai, United Arab
Emirates) with diagnosis of CVT were identified through ICD-9
coding system of the hospital medical records over a period of 16
years (1991–2007) and had their medical records reviewed. Data
from 1990 to 1996 were reviewed retrospectively, whereas data after
1996 were collected prospectively.
All patients underwent brain imaging (CT scan or MRI) and were
reviewed by trained neuroradiologists. Diagnosis was based on
established radiological criteria.14–20 Demographic, clinical, labora-
tory, and radiological data were recorded. Functional status was
recorded on modified Rankin scale21 at admission, discharge, and
latest follow-up, and was dichotomized as good (score of 0–2) or
poor (score 2). Outcome was dichotomized based on modified
Rankin scale with score of 0 to 2 considered as favorable; a score2
was unfavorable. The outcome was recorded at discharge from
hospital and at last available follow-up. In addition, in-hospital
mortality was recorded separately. Statistical analysis used descrip-
tive, univariate (2 and t test), and multivariate methods. Factors with
P0.2 on univariate analysis, influencing the outcome, were incor-
porated in a multiple logistic regression model (purposeful selection
method) to detect independent predictors of outcome. Data were
analyzed on SPSS version 14.0 (SPSS Inc).
Results
There were 109 patients enrolled from 4 centers (Aga Khan
University Hospital, Karachi, Pakistan: 59; Liaquat National
Hospital, Karachi, Pakistan: 20; Shifa International Hospital,
Islamabad, Pakistan: 11; and Rashid Hospital, Dubai, United
Arab Emirates: 19). Median age was 35 (mean, 35.7613.15;
range, 10–76) years, with 91 (83%) being younger than age
46 years. There were 58 (53%) females and 51 (47%) males;
the females were 5 years younger than the males (mean age
of women, 33.210.44; mean age of men, 38.6615.27
years). The most common presenting features were headache,
followed by focal motor deficits, seizures, and mental status
changes (Table 1). All but 7 patients were independent before
onset of symptoms of the index CVT, but only a 25% of
patients were independent at the time of admission (modified
Rankin score 3). The reason why large numbers of patients
were dependent at the time of admission is most likely
attributable to the tertiary care nature of these hospitals,
which tend to have sicker patients.
Median duration of presenting illness was 7 (1–200) days.
Median diagnostic delay from onset of illness was 10 (0–200)
days, and that after hospital admission was 1 (0–15) day.
Eighteen of 58 (31%) females were in postpartum period,
and 12 of these 18 (66%) presented within 2 weeks of their
delivery. Three of these 18 women underwent Cesarean
section (postoperative). Seven (12%) women were using oral
contraceptive pills (data were available for only 46 women).
Twenty (18%) had an infectious process (tuberculous men-
ingitis, 4; rhino-orbital fungal infection, 3; bacterial menin-
gitis, 2; mastoiditis, 2; malignant otitis externa, 1; nasal
pustule,1; periorbital cellulites, 1; gastroenteritis with dehy-
dration, 2; respiratory tract infection, 1; and urinary tract
infection, 1). Six patients had history of recent surgery,
including the 3 women who underwent Cesarean section.
Three patients had underlying acute lymphocytic leukemia (2
of these received L-asparaginase), 3 had ulcerative colitis,
and 1 each had non-Hodgkin lymphoma, myelodysplastic
syndrome, glomus jugulare tumor, and Bechet disease. Thir-
teen patients had hypercoagulopathy, and 1 had systemic
lupus erythromatosis (Table 2).
All patients underwent brain imaging. The most common
modality used was MRI of the brain (71%), followed by
MRV brain (66%), CT head (42%), 4-vessel cerebral digital
subtraction angiogram (5%), and CT angiography of the brain
Table 1. Clinical and Imaging Features
Clinical Features Frequency (%)
Headache 88 (81)
Focal motor deficits 49 (45)
Seizures 42 (39)*
Mental status changes 40 (37)†
Papilledema 38 (35)
Visual symptoms 17 (16)
Fever 17 (16)
Dysarthria 15 (14)
Radiologic Features (site of sinus involvement)
Superior sagittal sinus 77 (71)
Transverse sinus 51 (47)
Sigmoid sinus 34 (31)
Straight sinus 11 (10)
Deep cerebral veins 8 (3)
Cortical veins 7 (6)
Internal jugular vein 4 (4)
Cavernous sinus 4 (4)
*Six had focal, 19 had generalized, and 12 had focal onset secondarily
generalized. In 5 patients onset was unclear.
†Thirteen of these had coma.
Table 2. Autoimmune and Hypercoagulopathy Work-Up
Test Performed Patients†
Frequency of Positive
Results (%)*
Serum homocysteine 35 10 (29)
Protein C 32 2 (6)
Protein S 36 3 (8)
Antithrombin-III 27 2 (7)
Lupus anticoagulant 23 1 (4)
Antinuclear antibodies 39 1 (3)
Antidouble-stranded deoxyribonucleic
acid antibodies
31 1 (3)
Anticardiolipin antibodies 34 0 (0)
*Positive results mean either decreased protein C, protein S, antithrombin-III,
or elevated serum homocysteine level or elevated autoantibodies (antinuclear
antibodies, antidouble-stranded deoxyribonucleic acid antibodies, lupus anti-
coagulant, and anticardiolipin antibodies).
†Tests performed in these many patients.
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(2%). Seventy-two (66%) had infarctions and out of these 37
(34%) had hemorrhagic. Three patients had focal subarach-
noid hemorrhage. In 54 (50%) patients, only 1 sinus was
involved. Superior sagittal sinus was most commonly in-
volved sinus, followed by transverse and sigmoid sinuses
(Table 1).
Seventy-three of 109 (67%) received acute anticoagulation,
and their average median activated partial thromboplastin
time was 54.3 (mean, 55.1411.28) seconds. In addition, 10
(9%) received low-dose subcutaneous heparin for deep ve-
nous thrombosis prophylaxis and 10 (9%) received antiplate-
let agents. None of the patients underwent thrombolyses.
Antibiotics were administered to 28 (26%) of the patients.
Seven of 13 patients (54%) with either brain or ear, nose,
throat region infections received anticoagulation. None of
these patients died during hospital stay. Two patients with the
infections died during follow-up, and 1 of them received
anticoagulants. However, this death was not related to anti-
coagulation; the patient died of renal failure.
Sixteen of 18 (89%) of patients with postpartum CVT
underwent anticoagulation. Nine of the patients who under-
went anticoagulation had significant functional disability at
discharge. Follow-up was available for 14 patients, and 12
were independent in activities of daily living; 2 remained
significantly disabled. Two untreated postpartum CVT pa-
tients were independent at follow-up. No patient with post-
partum CVT died.
Thirty-seven patients had either acquired or hereditary
thrombophilia, and 27 (73%) of these received anticoagula-
tion. Sixteen (59%) of the patients who underwent anticoag-
ulation had poor outcome at discharge as compared to 4 of 10
(40%) who did not receive anticoagulation; however, this
difference was not statistically significant (P0.46).
Follow-up was available for 21 patients who underwent
anticoagulation. Sixteen of these (76%) were independent
compared to 8 of 9 (89%) untreated patients (P0.63). Two
of patients who underwent anticoagulation died during
follow-up, but their deaths were not related to anticoagula-
tion. Patients with thrombophilia had more extensive sinus
involvement as compared with patients without thrombo-
philia, ie, 25 of 37 (68%) patients with thrombophilia had
involvement of 1 sinus as compared with 30 of 72 (42%)
patients without thrombophilia (P0.01).
Ten patients had hyperhomocystinemia and 6 (60%) re-
ceived anticoagulation. One (17%) had poor outcome at
discharge as compared with 3 of 4 (75%) who did not receive
anticoagulation (P0.19). All 5 treated patients for whom
follow-up was available were independent at their last visit,
whereas 3 of 4 (75%) untreated patients were independent.
None of the patients with hyperhomocystinemia died.
Twenty-three (21%) patients’ conditions deteriorated dur-
ing hospital stay, and 4 of these underwent neurosurgical
intervention (frontal lobectomy in 2, hematoma evacuation in
1, and ventriculoperitoneal shunt in 1). Thirteen patients
received steroids, 7 received mannitol, and 3 received acet-
azolamide. Median hospital stay was 9 (1–59) days.
Fifty patients were either dead (n7; 4 males and 3
females) or disabled (modified Rankin score 2; n43) at
the time of discharge. None of patients with postpartum CVT
died. One of 4 patients with malignancy died during hospital
stay. Univariate analysis revealed that coma and focal motor
deficit at presentation, infarctions on imaging, and hemor-
rhagic conversion of infarction were associated with unfavor-
able outcome. There was also a trend that involvement of
deep cerebral venous system and fever at presentation were
associated with unfavorable outcome. However, on multivar-
iate analysis, only focal motor deficits (OR, 2.93; 95% CI,
1.2–7.5; P0.018) and hemorrhagic infarctions (OR, 2.81;
95% CI, 1.04–7.85; P0.041) were found to be independent
predictors of unfavorable outcome. There was also a trend
toward unfavorable outcome in patients with deep CVT (OR,
8.32; 95% CI, 0.9–76.38; P0.061) and coma (OR, 6.93;
95% CI, 0.76–62.76; P0.085).
Seven (6%) patients died during hospital stay. Coma was
found to be independent predictor of in-hospital mortality
(OR, 12.9; 95% CI, 2.05–80.83; P0.006). There was trend
that older age (age older than 45) was associated with
in-hospital mortality (OR, 4.5; 95% CI, 0.76 –26.34;
P0.095).
A median follow-up of 6 months (3 days to 5 years) was
available in 72 (66%) patients. Sixty-one of the 72 patients
(85%) were independent at their latest follow-up. Three (4%)
died and 8 (11%) remain dependent, with modified Rankin
score of 3. Coma at admission, functional status at dis-
charge from hospital, and hemorrhagic infarctions were found
to be significant factors associated with long-term outcome
on univariate analysis; however, only hemorrhagic infarction
turned out to be a significant factor of long-term unfavorable
outcome on multivariate analysis (OR, 5.87; 95% CI, 1.49–
23.02; P0.011).
Discussion
Clinical presentation of CVT is extremely variable, ranging
from isolated headache to focal deficits to encephalopathy to
psychiatric manifestations to coma.2,22 Clinical presentation
of our cohort is almost identical to what has been reported
from the west, with exception of mental status changes and
coma, which were more common in our cohort.5 Thirty-seven
percent of our patients had mental status changes including
drowsiness, confusion, and agitation, as compared to 22%
reported in ISCVT.5The ISCVT reports 14% of their
patients having either coma or stupor, but separate figures for
each were not mentioned. In our cohort, we noted that 13%
patients were comatose at presentation. The reason for this
difference is unclear, but a delayed presentation may be a
factor. We noted that 25% of patients were independent at
the time of admission. These patients were independent
because of milder disease, because only 2 had subtle focal
motor deficits and 1 had seizures. Three of these had small
hemorrhagic infarctions. The reason why large numbers of
patients were dependent at the time of admission is most
likely related to the tertiary care nature of these hospitals,
which tend to get sicker patients. We noted a median duration
from symptom onset to hospital presentation as 7 days, as
compared to 4 days in ISCVT study.5
Douglas et al23,24 reported that frequency of peripartum
intracranial venous thrombosis is 8.9 to 11.6 cases per
100 000 deliveries. In our cohort 31% of the females were in
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the postpartum state as opposed to 15% reported from the
west.5,25 Possible explanations for this difference include
home deliveries in unhygienic environments and certain
rituals, ie, water deprivation during immediate postpartum
period. In addition, because birth rates in our countries are
higher than in the west, we might see more postpartum
women.
Oral contraceptives have long been attributed to develop-
ment of CVT and have been reported in 54% to 71% of CVT
patients.5,25 In our study only 14% of women were using oral
contraceptives. This may simply reflect lack of use of oral
contraceptives in our region of the world.
Another small but significant difference was central ner-
vous system infections, which were noted in 5% of our
patients, as compared to 2% in ISCVT.5 However, overall
proportions of infections, including that of the ear/nose/throat
region and face, were similar to that reported in ISCVT.
Thrombophilia (genetic) is an important cause of CVT and
has been reported in 15% to 22% of patients with CVT.5,25
We noted genetic thrombophilia in only 5% of our patients.
This figure is not only lower than that reported from the west
but also lower than that reported by Asian countries like
Saudi Arabia. Daif et al,8 from Saudi Arabia, reported genetic
thrombophilia in 5 of 40 (12.5%) patients.
Hyperhomocystinemia is an important cause of hyperco-
agulopathy, which increases the risk of CVT by 4-fold.26
Plasma homocysteine was elevated in 10 (9%) of the total
patients, which is 2-times higher than that reported in
ISCVT.5 However, the test was performed in only 35 (32%)
of the patients in our study. The reason for this difference is
unclear. However, the hyperhomocystinemia may be more
prevalent in our countries, and this warrants an epidemiolog-
ical survey to confirm or refute this notion.
Only 67% of our patients received anticoagulation. This is
much lower than that reported in ISCVT, which reported 85%
as having received anticoagulation. This lower rate may
reflect physicians’ awareness and reluctance. We noted a
much higher death or dependency rate at discharge as
compared to that reported recently from the west, ie, 51% vs
19%. This is probably a reflection of severe disease at
presentation. The predictors of unfavorable outcome were
hemorrhagic infarctions and focal motor deficits. There was
also a trend that coma at presentation and involvement of
deep cerebral venous system was associated with poor out-
come. Similar trends have been reported in the literature.5,27
We noted a death rate of 8% at discharge, which is within
the range reported in literature, ie, 4.3% to 15%.5,26–28 We
found coma to be an independent predictor of death at
discharge, and there was also trend that older patients (older
than 45 years) were more likely to die during the hospital
stay.
Follow-up was available for 72 patients. Sixty-one (85%) had
no disability on follow-up. Proportion of complete or near-
complete recovery is similar to that reported earlier.5,27,28
Our study is limited by its partly retrospective nature and
lack of uniform evaluation in terms of work-up for hyperco-
agulopathy and autoimmune disorders. This is, however, the
limitation of an observational study with different investiga-
tional styles of the local neurologists.
To our knowledge, this is the largest published series of
CVT from our countries. We have noted some significant
differences in risk factor profile for this disease from that of
the west, ie, postpartum state, hyperhomocystinemia, and
central nervous system infections were more common in our
population. Oral contraceptive use is not a major risk factor in
our settings. For unclear reasons, use of anticoagulation is
low as compared to that in the west. This could be partly
because of infections related to CVT in patients in our series.
The overall outcome of those patients was poorer than any
reported series from western countries. This could be attrib-
utable to selection bias, because these cases are reported from
tertiary care centers. We suggest suspecting this disease in
every postpartum woman with neurological symptoms, and
we recommend evaluation for hyperhomocystinemia in cases
of CVT. We also recommend a careful search for central
nervous system, ear/nose/throat, face, and sinus infections in
the setting of CVT. In addition, identifying patients at high
risk for unfavorable outcomes may provide opportunity for
development of novel therapeutic paradigms including
thrombolysis (systemic versus endovascular) and early neu-
rosurgical interventions. Because there are important clinical,
etiologic, and therapeutic differences in Asian countries as
compared to countries in the west, there is a dire need for
well-conducted, large, multicenter, multinational, cohort
studies among Asian countries. Large, multicenter, online
registries are feasible because of advances in information
technology and international collaboration. These may be
helpful in identifying regional differences in CVT, as well as
for enrolling patients for future randomized trials.29
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